logo
ResearchBunny Logo
A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome

Medicine and Health

A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome

V. Tunali, N. Ç. Arslan, et al.

A multicenter randomized trial found that an AI-assisted, microbiome-based personalized diet delivered notable symptom relief, improved quality of life, and measurable gut microbiome diversity shifts compared with a low-FODMAP diet over six weeks. This research was conducted by Varol Tunali, Naciye Çiğdem Arslan, Beyza Hilal Ermiş, Gözde Derviş Hakim, Aycan Gündoğdu, Mehmet Hora, and Özkan Ufuk Nalbantoğlu.

00:00
00:00
~3 min • Beginner • English
Abstract
INTRODUCTION: Personalized management strategies are pivotal in addressing irritable bowel syndrome (IBS). This multicenter randomized controlled trial focuses on comparing the efficacy of a microbiome-based artificial intelligence-assisted personalized diet (PD) with a low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet (FODMAP) for IBS management. METHODS: One hundred twenty-one patients participated, with 70 assigned to the PD group and 51 to the FODMAP diet group. IBS subtypes, demographics, symptom severity (IBS-SSS), anxiety, depression, and quality of life (IBS-QOL) were evaluated. Both interventions spanned 6 weeks. The trial's primary outcome was the within-individual difference in IBS-SSS compared between intervention groups. RESULTS: For the primary outcome, there was a change in IBS-SSS of −112.7 for those in the PD group vs −99.9 for those in the FODMAP diet group (P=0.29). Significant improvement occurred in IBS-SSS scores (P<0.001), frequency (P<0.001), abdominal distension (P<0.001), and life interference (P<0.001) in both groups. Anxiety levels and IBS-QOL scores improved in both groups (P<0.001). PD reduced IBS-SSS across all subtypes (IBS-C P<0.001; IBS-D P=0.01; IBS-M P<0.001), whereas the FODMAP diet showed comparable improvements in IBS-C (P=0.004) and IBS-M (P<0.001). PD improved IBS-QOL in all subtypes (IBS-C P<0.001; IBS-D P<0.001; IBS-M P=0.008), while FODMAP improved IBS-QOL in IBS-C (P=0.004) and IBS-D (P=0.022). PD led to significant microbiome diversity shifts (P<0.05) and taxa alterations compared with FODMAP. DISCUSSION: The AI-assisted PD emerges as a promising approach for comprehensive IBS management, demonstrating symptom relief, enhanced QOL, and notable diversity shifts in the gut microbiome.
Publisher
The American Journal of Gastroenterology
Published On
May 08, 2024
Authors
Varol Tunali, Naciye Çiğdem Arslan, Beyza Hilal Ermiş, Gözde Derviş Hakim, Aycan Gündoğdu, Mehmet Hora, Özkan Ufuk Nalbantoğlu
Tags
Irritable Bowel Syndrome (IBS)
AI-assisted personalized diet
Low-FODMAP diet
Gut microbiome diversity
Randomized controlled trial
IBS-SSS symptom score
Quality of life (IBS-QOL)
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny